🔴 Fennec Pharmaceuticals is trading 5% down today amid biotech weakness after disappointing Ionis trial news

Fennec Pharmaceuticals is trading at $10.17, down -5.13%, as biotech weakness intensified after disappointing Ionis Pharmaceuticals trial news.

• No company-specific negative announcement was identified for September 15, 2026.
• Broader risk-off trading, rising Treasury yields, oil above $105, and Federal Reserve uncertainty are weighing on growth-oriented stocks.
• Fennec Pharmaceuticals is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference at 11:30 a.m. EDT.